|
Alkermes Plc (NASDAQ: ALKS) |
|
Alkermes Plc
ALKS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Alkermes Plc 's sales fell
by -0.73 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2274
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Alkermes Plc 's net income grew by 93.44 % in III. Quarter 2024 year on year, above company average,
• More on ALKS's Growth
|
|
Alkermes Plc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Alkermes Plc PEG ratio is at 0.3
Alkermes Plc realized cash reduction of $ -1.51 per share in trailing twelve-month period. |
Company |
16.61 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.55.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.41.
• More on ALKS's Valuation
|
|
|
|
|
Alkermes Plc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Alkermes Plc PEG ratio is at 0.3
Alkermes Plc realized cash outflow of $ -1.51per share in trailing twelve-month period. |
Company |
16.61 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.55.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.41.
Alkermes Plc Price to Book Ratio is at 4.13 lower than Industry Avg. of 82.25. and higher than S&P 500 Avg. of 0.02
• More on ALKS's Valuation
|
|
ALKS's Profitability Comparisons
|
Alkermes Plc achieved increase in profitability, decrease in demand. Operating Margin grew in III. Quarter 2024 to 27.7 % from 27.53 % in II. Quarter.
Alkermes Plc net profit margin of 24.43 % is currently ranking no. 23 in Major Pharmaceutical Preparations industry, ranking no. 42 in Healthcare sector and number 547 in S&P 500.
Profitability by Segment |
Total |
24.43 % |
|
|
Alkermes Plc achieved increase in profitability, decrease in demand. Operating Margin grew in III. Quarter 2024 to 27.7 % from 27.53 % in II. Quarter.
Alkermes Plc net profit margin of 24.43 % is currently ranking no. 23 in Major Pharmaceutical Preparations industry, ranking no. 42 in Healthcare sector and number 547 in S&P 500.
• More on ALKS's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com